COMPANY:

Biovica

"Biovica...has signed a Master Service Agreement (MSA) with a US-based biotech company...Under the agreement, Biovica will provide TKa testing services utilizing Biovica’s DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support drug development and dosage optimization. The agreement will expand DiviTum TKa’s inclusion into a growing list of clinical trials investigating the potential of next generation CDK inhibitor treatment and therefore further increase the likelihood of establishing TKa as a monitoring companion biomarker."

"Biovica...announces that results with DiviTum® TKa from the Spanish GEICAM/2014-12 FLIPPER trial will be presented at the world’s largest cancer conference, the annual ASCO meeting on June 2, 2024 9:00 AM – 12:00 PM CDT. The data supports the use of DiviTum TKa to predict outcome and progression on first line treatment HR+ metastatic breast cancer (MBC) patients providing important clinical information about treatment benefit."

"Biovica...announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring."

"Biovica...has received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times."

"Biovica...announces that a clinical trial, BettER, is being launched at Washington University School of Medicine in St. Louis. The study is aimed at evaluating whether patients with HR+ HER2- metastatic or unresectable breast cancer benefit from DiviTum® TKa."

"Biovica...has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several work orders, the first of which is 1.2 MSEK."

"Biovica said Thursday that the firm and an undisclosed pharmaceutical company have signed a master service agreement that will allow use of Biovica's cell proliferation assay and testing services in drug development studies starting with a work order worth SEK 1.7 million ($166,000)."